Status:
COMPLETED
Efficacy of Using Interleukin-2 in Antiretroviral Naïve HIV Patients (ANRS119)
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis
Collaborating Sponsors:
Chiron Corporation
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Interleukin-2 (IL-2) increases the number of CD4 cells in HIV-1 infected patients under highly active antiretroviral therapy (HAART) with a CD4 cell count over 200/mm3, but its activity in patients wi...
Detailed Description
IL-2 is produced naturally in the body and helps CD4 cells multiply. In earlier studies in HIV-infection, most of the patients with a controlled viral load under antiretroviral therapy and a high leve...
Eligibility Criteria
Inclusion
- Adult patients with proven HIV-1-infection
- No prior exposition to antiretrovirals
- CD4 cell count between 300 and 500/mm3
- Signed written inform consent
Exclusion
- Pregnancy
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
End Date :
November 1 2006
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT00120185
Start Date
December 1 2003
End Date
November 1 2006
Last Update
December 22 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service des Maladies Infectieuses
Paris, France, 75010